Constructs a prokaryotic expression vector encoding two linked TB4 genes to produce a cost-effective recombinant TB4 dimer. Pilot-scale E. coli fermentation yielded dimeric TB4 at enhanced purity; the dimer showed superior cell migration promotion and wound healing acceleration versus monomeric TB4 in dermal wound models. Independently validates the pharmacological advantage of TB4 dimerization established in the cardiac study (PMID 29550018)—demonstrating that dimeric architecture provides consistent enhancement across multiple TB4 therapeutic applications including skin wound healing.
Xu, Tian-Jiao; Wang, Qi; Ma, Xiao-Wen; Zhang, Zhen; Zhang, Wei; Xue, Xiao-Chang; Zhang, Cun; Hao, Qiang; Li, Wei-Na; Zhang, Ying-Qi; Li, Meng